Navigation Links
Neurochem reports results for fourth quarter and fiscal year 2007 and important advances on corporate objectives
Date:2/20/2008

Neurochem will host a conference call Thursday, February 21, 2008, at 8:30

A.M. ET.

LAVAL, QC, Feb. 20 /PRNewswire-FirstCall/ - Neurochem Inc. (NASDAQ: NRMX; TSX: NRM) reports results for the fourth quarter and fiscal year ended December 31, 2007, and announces important advances regarding the Company's pharmaceutical and nutraceutical activities. The Company reports, for the fourth quarter, a net loss of $16,097,000 ($0.33 per share), compared to $17,011,000 ($0.44 per share) for the corresponding period in the previous year. For the year ended December 31, 2007, the net loss amounted to $81,486,000 ($1.85 per share), compared to $66,469,000 ($1.72 per share) for the same period last year. The net loss for the year ended December 31, 2007, includes a non-recurring charge in the second quarter of fiscal 2007 under Canadian GAAP of $10,430,000 relating to the $40 million 5% senior subordinated convertible notes, which were fully converted into common shares during the second quarter of 2007. In total, accretion expense amounted to $15,751,000 for the year ended December 31, 2007. As at December 31, 2007, the Company had available cash, cash equivalents and marketable securities of $58,672,000, compared to $48,758,000 at December 31, 2006. All figures are in U.S. dollars, unless otherwise specified.

Furthermore, the Company is pleased to announce the following important developments:

- The regulatory submission for the initiation of the Phase II clinical

trial with the investigational product candidate NC-503 in patients

with Type II Diabetes as well as certain features of Metabolic Syndrome

was accepted by the Therapeutic Products Directorate of Health Canada.

As a result, the first patient is expected to be enrolled shortly. The

key objectives of the study are to investigate the safety and proof-

of-concept efficacy of NC-503 on glycemic measures.

<
'/>"/>
SOURCE NEUROCHEM INC.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21

Related medicine news :

1. Neurochem to present at 2008 BIO CEO & Investor Conference - Presentation will be Web cast live
2. Neurochem appoints Mr. Gary Schmid as CEO of new nutraceutical business
3. Neurochem to present at JPMorgan Healthcare Conference
4. Neurochem announces European opinion for Eprodisate (KIACTA(TM)) for the treatment of AA amyloidosis
5. Neurochem announces eprodisate (KIACTA(TM)) receives acknowledgement of complete response and is granted Class 2 review
6. Neurochem announces departure of Dr. Philippe Calais, President, Global Business
7. Neurochem reports results for third quarter of fiscal 2007
8. Emageon Reports Fourth Quarter and 2007 Financial Results
9. Cyberonics Reports Operating Profit for Third Quarter FY08 and Announces Share Repurchase Program
10. Platinum Underwriters Holdings, Ltd. Reports Record Fourth Quarter and Year Ended December 31, 2007 Financial Results
11. Onyx Pharmaceuticals Reports Fourth Quarter and Twelve-Month 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... Dennis Thompson HealthDay Reporter ... fruits and vegetables are vital to good health and a ... hit five servings of fruits and vegetables each day, additional ... review suggests. The human body may only be able ... every day, limiting its ability to absorb important nutrients from ...
(Date:7/30/2014)... FL (PRWEB) July 30, 2014 ... doctoral candidate Renee Gordon and biochemistry professor Ngozi ... to conduct research as Fulbright Scholars. The prestigious ... education exchange program that awards grants to students, ... and conduct research abroad. Both Gordon and Ugochukwu ...
(Date:7/30/2014)... BuyCBDOnline.co , the web's leading ... to announce that it is has made available through ... products available for immediate shipping. , "We have to ... stages," site founder Jason Liss says. "For being such ... of unique products that are available or will be ...
(Date:7/30/2014)... July 30, 2014 The Independent ... will be holding 5 free financial workshops in the ... The goal of these workshops is our collective ... heights of financial empowerment. , These workshops were designed ... Kiyosaki, a successful investor, entrepreneur, and bestselling author (Rich ...
(Date:7/30/2014)... 2014 With the accelerated aging ... health expenditure as well as the improved medical ... diagnostic reagent industry has been developing quickly, especially ... 2013, Chinese in vitro diagnostics market size reached ... in vitro diagnostic reagents. , Chinese in ...
Breaking Medicine News(10 mins):Health News:Fruits, Veggies May Have Their Limits in Boosting Lifespan 2Health News:Fruits, Veggies May Have Their Limits in Boosting Lifespan 3Health News:FAMU Professor and Engineering Student Named Fulbright Scholars 2Health News:FAMU Professor and Engineering Student Named Fulbright Scholars 3Health News:Delicious, Unique CBD-Rich Hemp Oil Product Debuts from BuyCBDOnline.co 2Health News:Delicious, Unique CBD-Rich Hemp Oil Product Debuts from BuyCBDOnline.co 3Health News:The Independent Woman is Coming to the San Francisco Area in August - Women Helping Women Reach Their Financial Goals 2Health News:The Independent Woman is Coming to the San Francisco Area in August - Women Helping Women Reach Their Financial Goals 3Health News:China Diagnostic Reagent Industry (biochemical, molecular & immunodiagnostic) 2016 Forecasts in New Research Report at ChinaMarketResearchReports.com 2Health News:China Diagnostic Reagent Industry (biochemical, molecular & immunodiagnostic) 2016 Forecasts in New Research Report at ChinaMarketResearchReports.com 3Health News:China Diagnostic Reagent Industry (biochemical, molecular & immunodiagnostic) 2016 Forecasts in New Research Report at ChinaMarketResearchReports.com 4
... Cutting out a can per day brought measurable benefits, study ... small reduction per day in sweetened soft drink intake could ... study, researchers found a measurable reduction in blood pressure -- ... 120/80 desired reading, and 1.1 points in diastolic pressure -- ...
... ... ... 2010 -- Prize4Life ( www.prize4life.org ), a nonprofit organization founded to accelerate the discovery of ... gala and charity auction at the Roger Smith Hotel on Thursday, May 27. The auction ...
... ... serving patients, healthcare providers and payers in region. , ... Philadelphia, PA (PRWEB) May 10, ... infusion services company, focused on providing complex pharmaceutical products and clinical services to ...
... ... Gets Improvements in Global Content, Search Algorithms, and Analysis Tools , ... Boston, MA (Vocus) May 24, 2010 ... IP -- the latest version of its online IP sequence search product. , ...
... researchers find , MONDAY, May 24 (HealthDay News) -- ... a choir could be just what the doctor ordered, ... of relaxation commonly associated with choir participation might actually ... disorder, at least in the short-run, study author Christina ...
... ... While Minimizing the Need for Extensive Healing and Recovery Time , ... Los Angeles, Calif. (PRWEB) May 24, ... considering aesthetic procedures is, “How long will it take to heal and recover?” For ...
Cached Medicine News:Health News:Fewer Sugary Drinks, Less High Blood Pressure 2Health News:Fewer Sugary Drinks, Less High Blood Pressure 3Health News:Prize4Life hosts &#8220;Art, Life, Spring&#8221; gala and auction to support fight against ALS/Lou Gehrig's Disease 2Health News:Prize4Life hosts &#8220;Art, Life, Spring&#8221; gala and auction to support fight against ALS/Lou Gehrig's Disease 3Health News:Greater Philadelphia Chamber Welcomes Pentec Health, Incorporated as New Member 2Health News:Greater Philadelphia Chamber Welcomes Pentec Health, Incorporated as New Member 3Health News:GenomeQuest Upgrades Online Patent Searching 2Health News:GenomeQuest Upgrades Online Patent Searching 3Health News:Choir Singing May Relieve Irritable Bowel Syndrome 2Health News:New Laser Treatment Offers Revolutionary Response to Aesthetic Procedure Candidates' Number One Concern: Recovery Time 2
(Date:7/29/2014)... 2014 Pfenex Inc. (NYSE MKT: PFNX) today announced ... of 8,333,333 shares of its common  stock at a price ... common stock was offered by Pfenex. In addition, Pfenex has ... 1,250,000 additional shares of common stock at the initial public ... the NYSE MKT under the symbol "PFNX." ...
(Date:7/29/2014)... ST. PAUL, Minn. , July 29, 2014 /PRNewswire/ ... of medical devices using neuroblocking technology to treat obesity, ... it will host a conference call on Thursday, August ... financial results for the second quarter ended June 30, ... Conference Call Details The second quarter conference ...
(Date:7/29/2014)... Calif., July 29, 2014 Edwards Lifesciences Corporation (NYSE: ... of heart valves and hemodynamic monitoring, today reported net income ... or $5.09 per diluted share, and non-GAAP net income of ... the same period a year earlier was $93.3 million, or ... million, or $0.84 per diluted share.  Net ...
Breaking Medicine Technology:Pfenex Announces Closing of Initial Public Offering 2EnteroMedics to Host Second Quarter 2014 Financial Results and Business Update Conference Call 2EnteroMedics to Host Second Quarter 2014 Financial Results and Business Update Conference Call 3Edwards Lifesciences Reports Strong Second Quarter Results 2Edwards Lifesciences Reports Strong Second Quarter Results 3Edwards Lifesciences Reports Strong Second Quarter Results 4Edwards Lifesciences Reports Strong Second Quarter Results 5Edwards Lifesciences Reports Strong Second Quarter Results 6Edwards Lifesciences Reports Strong Second Quarter Results 7Edwards Lifesciences Reports Strong Second Quarter Results 8Edwards Lifesciences Reports Strong Second Quarter Results 9Edwards Lifesciences Reports Strong Second Quarter Results 10Edwards Lifesciences Reports Strong Second Quarter Results 11Edwards Lifesciences Reports Strong Second Quarter Results 12Edwards Lifesciences Reports Strong Second Quarter Results 13Edwards Lifesciences Reports Strong Second Quarter Results 14Edwards Lifesciences Reports Strong Second Quarter Results 15Edwards Lifesciences Reports Strong Second Quarter Results 16Edwards Lifesciences Reports Strong Second Quarter Results 17Edwards Lifesciences Reports Strong Second Quarter Results 18Edwards Lifesciences Reports Strong Second Quarter Results 19Edwards Lifesciences Reports Strong Second Quarter Results 20Edwards Lifesciences Reports Strong Second Quarter Results 21Edwards Lifesciences Reports Strong Second Quarter Results 22Edwards Lifesciences Reports Strong Second Quarter Results 23Edwards Lifesciences Reports Strong Second Quarter Results 24Edwards Lifesciences Reports Strong Second Quarter Results 25
... the Barbara Ann Karmanos Cancer Institute in Detroit ... Cancer Research,s 100th Annual Meeting 2009 that could ... suffer from a more deadly form of acute ... Xie, Ph.D., presented a poster at the conference ...
... 21 ImQuest BioSciences and Arisyn Therapeutics jointly ... the National Institutes of Health to support the ... treatment of hepatitis C virus (HCV) infection. ... mechanism of action of ATI-0810 (Formerly PG301029) and ...
Cached Medicine Technology:Karmanos Cancer Institute Researchers Study New Drug Combinations to Treat Childhood Leukemia 2Karmanos Cancer Institute Researchers Study New Drug Combinations to Treat Childhood Leukemia 3ImQuest BioSciences Receives Phase I SBIR Grant to Develop a Novel Hepatitis C Virus Therapeutic Agent 2
Inquire...
Provides maximum comfort upon insertion through ultra-smooth catheter eyelets--formed with advanced ultrasonic technology....
... A fast, reliable and accurate immunoassay for ... plasma. , ,The fully automated Elecsys proBNP ... in symptomatic patients. NT-proBNP levels also indicate ... the assessment of prognosis. In addition, NT-proBNP ...
... Warming Tube is a cost-effective method of ... to your patient. The warming tube is ... OR, Cath. Lab., and Radiology. The CSZ ... to warm patients since it may be ...
Medicine Products: